Valneva SE, a specialty vaccine company, and Pfizer have entered a collaboration to develop and commercialize Valneva’s Lyme disease vaccine candidate VLA15, which is currently in Phase 2 clinical studies.    VLA15 is an active Lyme disease vaccine program in clinical development that covers six serotypes that are prevalent in North America and Europe. The investigational multivalent protein subunit vaccine, VLA15, targets the outer surface protein A (OspA) of Borrelia, an established mechanism ...